Trial · NCT03449446
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | Selonsertib | 84.6 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | Firsocostat | 85.0 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | Cilofexor | 92.5 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | SEL + FIR | 88.6 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | SEL + CILO | 96.1 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | FIR + CILO | 91.0 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | Placebo | 79.5 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Selonsertib | 94.9 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Firsocostat | 100.0 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Cilofexor | 97.5 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | SEL + FIR | 98.7 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | SEL + CILO | 96.1 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | FIR + CILO | 100.0 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Placebo | 94.9 | percentage of participants | ||
| Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48 | Selonsertib | 28.6 | 95% Confidence Interval 3.7 to 71.0 | percentage of participants | |
| Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48 | Firsocostat | 12.1 | 95% Confidence Interval 3.4 to 28.2 | percentage of participants | |
| Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48 | Cilofexor | 11.8 | 95% Confidence Interval 3.3 to 27.5 | percentage of participants | |
| Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48 | SEL + FIR | 15.5 | 95% Confidence Interval 8.0 to 26.0 | percentage of participants | |
| Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48 | SEL + CILO | 19.1 | 95% Confidence Interval 10.6 to 30.5 | percentage of participants | |
| Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48 | FIR + CILO | 20.9 | 95% Confidence Interval 11.9 to 32.6 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03449446/results